Help your eligible HR+/HER2– aBC patients achieve
their treatment goals

In an exploratory analysis, 1L KISQALI + ET was observed to increase mOS by 11 months vs placebo + ET in pre/perimenopausal patients1 This was an exploratory OS analysis for the NSAI subgroup with an extended median follow-up of 54 months.1 At median 54-month follow-up, mOS was 58.7 months with KISQALI + ET vs 47.7 months with placebo + ET (HR=0.80; 95% CI: 0.62–1.04)1 1L KISQALI + ET demonstrated an OS benefit in pre/perimenopausal patients from a dedicated randomised controlled trial vs ET + placebo2 The estimated OS at 42-month follow-up was 70.2% (95% CI: 63.5–76.0) in the KISQALI + ET group and 46.0% (95% CI: 32.0–58.9) in the placebo + ET group (HR=0.71; 95% CI: 0.54–0.95; p=0.00973 by log-rank test).2

ET refers to LHRH plus either NSAI or tamoxifen.

KISQALI is not recommended to be used in combination with tamoxifen.3

1L, first-line; aBC, advanced breast cancer; AI, aromatase inhibitor; CI, confidence interval; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; mOS, median overall survival; NSAI, non-steroidal aromatase inhibitor; OS, overall survival.